Bladder Cancer Clinical Trial

HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

Summary

This study is being done to learn about urothelial cancers that make HER2 and how that affects treatment choices for participants with urothelial cancer. During this study, the medical and health records of participants will be reviewed to learn more about their health.

Participants will have urothelial cancer that has grown in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically confirmed UC originating from the renal pelvis, ureters, bladder, or urethra. Mixed-cell type tumors are eligible as long as urothelial cell carcinoma is the predominant cell type.
Locally advanced unresectable or metastatic stage disease
Formalin fixed paraffin embedded (FFPE) tumor tissue blocks (or freshly sectioned slides, see laboratory manual for details) available for HER2 testing.
At least 1 prior line of systemic therapy for locally advanced unresectable or metastatic urothelial carcinoma (LA/mUC), including 1 line of platinum-containing chemotherapy.
Initiation of anticancer therapy for UC after prior progression on platinum-based therapy with or without maintenance avelumab between 01 January 2019 and 12 months before the end of data collection
Radiographically documented and measurable disease progression immediately before index date

Exclusion Criteria:

Any concurrent malignant neoplasm requiring systemic therapy during the study window
Enrollment in a therapeutic clinical trial and received non-standard of care treatment during index line of therapy

Study is for people with:

Bladder Cancer

Estimated Enrollment:

350

Study ID:

NCT05902494

Recruitment Status:

Recruiting

Sponsor:

Seagen Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

University of California Irvine
Orange California, 92868, United States More Info
Nataliya Mar
Principal Investigator
University of California San Francisco
San Francisco California, 94158, United States More Info
Vadim Koshkin
Principal Investigator
University of Colorado
Aurora Colorado, 80045, United States More Info
Laura Graham
Principal Investigator
Avera
Sioux Falls South Dakota, 57105, United States More Info
Casey Williams
Principal Investigator
Hospital Center University De Rouen
Rouen , 76000, France More Info
Christian Pfister
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Bladder Cancer

Estimated Enrollment:

350

Study ID:

NCT05902494

Recruitment Status:

Recruiting

Sponsor:


Seagen Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.